Fractional Senior Specialist, Regulatory Programs
GeneFab
Alameda, CA•$85-$95/hr
Project ManagementQuality AssuranceChief Marketing Officer
GeneFab
GeneFab offers its customers an extensive technology platform and know-how that spans early stage product design, technical development, and cGMP compliant production. GeneFab's technology platform includes bioinformatic-guided discovery of cell type promoters, directed evolution of small molecule-regulated gene switches, and the engineering of highly sensitive kill switches for enhanced safety and control of cellular therapies.
- Est. revenue
- $10M–$20M
- Latest round
- Series Unknown
- Employees
- 59
Funding & revenue at GeneFab
How well capitalized the business is — useful context before you scope a fractional engagement or negotiate a rate.
Estimated annual revenue
$10M–$20M
Modeled range, not company-reported
Latest round
Series Unknown
Jan 2026
Investors
K5 Global
Growth signals
How fast GeneFab is adding people, roles, and audience.
Employees
59
Reported band 51-200
Open roles
4
0% year over year
LinkedIn followers
3K
+98% year over year
Headcount change
- MoM
- +7.3%
- QoQ
- +3.5%
- 6mo
- -4.8%
- YoY
- -21.3%
- 2yr
- -11.9%
+4 people
+2 people
-3 people
-16 people
-8 people
Team composition
Where GeneFab concentrates its people — a read on which function a fractional leader would plug into.
By function
- Quality Assurance1627%
- Research1322%
- Operations814%
- Business Development610%
- Engineering35%
- Community And Social Services23%
- Finance12%
- Marketing12%
By region
- United States57
- California, United States53
- San Francisco Bay Area52
- San Francisco, CA10
- Alameda, CA9
- Singapore3
Inside GeneFab
What the business focuses on, where it operates, and how employees rate it.
Specialties
Cell TherapyGene TherapySynthetic BiologymRNA & LNPSynthetic Biology Target Discovery Outsourced R&D
Categories
BiotechnologyInterior DesignManufacturing
Markets
PRIVATE
GeneFab in the news
Recent coverage picked up alongside the firmographic refresh.
- GeneFab Launches Cell-Specific Synthetic Promoters and Drug-Induced Switches to Enhance the Safety and Efficacy of in vivo Cellular Therapies
May 2026
- DNA Island: Alameda is attracting biotechs amid an industrywide downturn
May 2025
- GeneFab & RegCell Partner for Treg Therapy Manufacturing in the U.S.
May 2025
- GeneFab Announces Two Presentations at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting 2024
Apr 2024
Jobs
1Funding, revenue, headcount, and hiring figures are third-party estimates from public sources and are not confirmed by the company. Last refreshed September 20, 2026.
About this page
This company page is automatically generated based on publicly available job postings. Company information is sourced from publicly available data and may not be complete. If you represent GeneFab, you can claim this page to manage and enhance it.